Systemic Minoxidil Accidental Exposure in a Paediatric Population: A Case Series Study of Cutaneous and Systemic Side Effects
Abstract
:1. Introduction
2. Materials and Methods
2.1. Inclusion and Exclusion Criteria
2.2. Variables of Interest
2.2.1. Main Variables
2.2.2. Other Variables of Interest
2.3. Statistical Analysis
3. Results
3.1. Sociodemographic and Clinical Features of the Sample
3.2. Factors Associated to the Appearance of Hypertrichosis
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
Appendix A
Patient Number | Age | Gender | Weight (kg) | Duration of Treatment (Days) | Dosage Schedule * [Treatment Indication] | Total Amount of Drug Administered ** | Development of Hypertrichosis | Other Skin Side Effects | Systemic Side Effects |
---|---|---|---|---|---|---|---|---|---|
1 | 2 months | Male | 4.7 | 30 | 10 mg/day (2.12 mg/kg/day) [GER] | 300 mg | Yes | No | No |
2 | 7 months | Female | 7 | 120 | 8 mg/day (1.14 mg/kg/day) [GER] | 960 mg | Yes | No | No |
3 | 8 months | Male | 7.8 | 5 | 8 mg/day (1.03 mg/kg/day) [GER] | 40 mg | No | No | No |
4 | 1 year and 2 months | Female | 10.2 | 60 | 8.5 mg/day (0.85 mg/kg/day) [GER] | 510 mg | Yes | No | No |
5 | 1 year and 2 months | Female | 9 | 30 | 10 mg/day (1.11 mg/kg/day) [GER] | 300 mg | No | No | No |
6 | 1 year and 3 months | Female | 10 | 30 | 5 mg/day (0.5 mg/kg/day) [GER] | 150 mg | Yes | No | No |
7 | 1 year and 6 months | Male | 10 | 7 | 10 mg/day (1 mg/kg/day) [CORT-Kawasaki] | 70 mg | Yes | No | No |
8 | 1 year and 7 months | Male | 11 | 120 | 15 mg/day (1.36 mg/kg/day) [GER] | 1800 mg | Yes | Yes (changes in hair colour) | No |
9 | 1 year and 8 months | Male | 11.5 | 20 | 12 mg/day (1.04 mg/kg/day) [GER] | 240 mg | Yes | No | No |
10 | 1 year and 11 months | Female | 13 | 60 | 5 mg/day (0.38 mg/kg/day) [GER] | 300 mg | No | No | Yes (diarrhoea, anxiety) |
11 | 1 year and 11 months | Female | 10 | 120 | 15 mg/day (1.5 mg/kg/day) [GER] | 1800 mg | Yes | No | No |
12 | 6 years | Female | 22 | 5 | 20 mg/day (0.91 mg/kg/day) [H. Pylori] | 100 mg | No | No | Yes (headache, facial oedema) |
13 | 7 years | Male | 30 | 4 | 10 mg/day (0.33 mg/kg/day) [CORT-NS] | 40 mg | No | No | No |
14 | 7 years and 8 months | Male | 25 | 30 | 16 mg/day (0.64 mg/kg/day) [GER] | 480 mg | Yes | Yes (changes in hair colour) | Yes (severe asthenia) |
15 | 8 years and 5 months | Female | 27 | 30 | 20 mg/day (0.74 mg/kg/day) [H. Pylori] | 600 mg | Yes | No | No |
16 | 9 years and 2 months | Male | 30 | 12 | 20 mg/day (0.67 mg/kg/day) [GER] | 240 mg | No | No | No |
17 | 9 years and 3 months | Male | 29 | 15 | 20 mg/day (0.69 mg/kg/day) [H. Pylori] | 300 mg | Yes | No | No |
18 | 2 years | Male | 14.5 | 14 | 7.5mg / day (0.52 mg/kg/day) [GER] | 105 mg | Yes | No | No |
19 | 13 years | Male | 36.5 | 14 | 40 mg/day (1.10 mg/kg/day) [GER] | 560 mg | No | No | No |
20 | 2 years | Male | 9.6 | 40 | 4.5 mg/day (0.47 mg/kg/day) [GER] | 180 mg | Yes | No | No |
Appendix B
Patient Number | Duration of Treatment (Days) | Total Amount of Drug Administered | Onset Latency Time of Hypertrichosis * (Days) | Initial Location | Locations Finally Affected | Resolution (After 6 Months) | Latency Time for Resolution ** (Days) |
---|---|---|---|---|---|---|---|
1 | 30 | 300 mg | 35 | Inferior limbs, pretibial location | Face, neck, back, superior/inferior limbs | No | - |
2 | 120 | 960 mg | 30 | Back | Face, back, superior/inferior limbs | Yes | 90 |
4 | 60 | 510 mg | 30 | Forehead | Face, neck, back, superior limbs | Yes | 90 |
6 | 30 | 150 mg | 15 | Forehead and temples | Face, chest, back, abdomen, superior/inferior limbs | No | - |
7 | 7 | 70 mg | 15 | Forehead, temples, superior lip | Face, back | Yes | 50 |
8 | 120 | 1800 mg | 30 | Forehead | Face, neck, chest, back, superior/inferior limbs | No | - |
9 | 20 | 240 mg | 7 | Temples | Face, back | Yes | 90 |
11 | 120 | 1800 mg | 75 | Superior/inferior limbs | Face, superior/inferior limbs | Yes | 40 |
14 | 30 | 480 mg | 10 | Forehead | Face, neck, chest, back, superior limbs | No | - |
15 | 30 | 600 mg | 45 | Superior lip | Face, neck, chest, back, superior/inferior limbs | No | - |
17 | 15 | 300 mg | 7 | Temples | Face, neck | Yes | 130 |
18 | 14 | 105 mg | 7 | Forehead | Face, back, inferior limbs | Yes | 60 |
20 | 40 | 180 mg | 10 | Back | Face, back, inferior limbs | Yes | 60 |
References
- Randolph, M.; Tosti, A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. J. Am. Acad. Dermatol. 2021, 84, 737–746. [Google Scholar] [CrossRef] [PubMed]
- Beach, R.A. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C’s of oral therapy. Dermatol. Ther. 2018, 31, e12707. [Google Scholar]
- Perera, E.; Sinclair, R. Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. F1000Research 2017, 6, 1650. [Google Scholar] [CrossRef] [PubMed]
- Lemes, L.R.; Melo, D.F.; de Oliveira, D.S.; de La-Rocque, M.; Zompero, C.; Ramos, P.M. Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far? Dermatol. Ther. 2020, 33, e13950. [Google Scholar] [CrossRef] [PubMed]
- Campese, V.M. Minoxidil: A review of its pharmacological properties and therapeutic use. Drugs 1981, 22, 257–278. [Google Scholar] [CrossRef]
- Suchonwanit, P.; Thammarucha, S.; Leerunyakul, K. Minoxidil and its use in hair disorders: A review. Drug. Des. Devel. Ther. 2019, 13, 2777–2786. Available online: https://pubmed.ncbi.nlm.nih.gov/31496654 (accessed on 26 August 2021). [CrossRef] [Green Version]
- Abell, E. Histologic response to topically applied minoxidil in male-pattern alopecia. Clin. Dermatol. 1988, 6, 191–194. [Google Scholar] [CrossRef]
- Lachgar, S.; Charveron, M.; Gall, Y.; Bonafe, J.L. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br. J. Dermatol. 1998, 138, 407–411. [Google Scholar] [CrossRef]
- Yano, K.; Brown, L.F.; Detmar, M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J. Clin. Investig. 2001, 107, 409–417. [Google Scholar] [CrossRef] [Green Version]
- Yum, S.; Jeong, S.; Kim, D.; Lee, S.; Kim, W.; Yoo, J.-W.; Kim, J.-A.; Kwon, O.S.; Kim, D.-D.; Min, D.S.; et al. Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase. Int. J. Mol. Sci. 2018, 19, 53. [Google Scholar] [CrossRef] [Green Version]
- Anderson, R.J.; Kudlacek, P.E.; Clemens, D.L. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem. Biol. Interact. 1998, 109, 53–67. [Google Scholar] [CrossRef]
- Goren, A.; Sharma, A.; Dhurat, R.; Shapiro, J.; Sinclair, R.; Situm, M.; Kovacevic, M.; Skudar, V.L.; Goldust, M.; Lotti, T.; et al. Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. Dermatol. Ther. 2018, 31, e12741. [Google Scholar] [CrossRef]
- Georgala, S.; Befon, A.; Maniatopoulou, E.; Georgala, C. Topical use of minoxidil in children and systemic side effects. Dermatology 2007, 214, 101–102. [Google Scholar] [CrossRef] [PubMed]
- Claudet, I.; Cortey, C.; Honorat, R.; Franchitto, N. Minoxidil topical solution: An unsafe product for children. Pediatr. Emerg. Care. 2015, 31, 44–46. [Google Scholar] [CrossRef] [PubMed]
- Kassai, B.; Bouyé, P.; Gilbert-Dussardier, B.; Godart, F.; Thambo, J.-B.; Rossi, M.; Cochat, P.; Chirossel, P.; Luong, S.; Serusclat, A.; et al. Minoxidil versus placebo in the treatment of arterial wall hypertrophy in children with Williams Beuren Syndrome: A randomized controlled trial. BMC Pediatr. 2019, 19, 170. Available online: https://pubmed.ncbi.nlm.nih.gov/31138170 (accessed on 26 August 2021). [CrossRef] [PubMed]
- Strife, C.F.; Quinlan, M.; Waldo, F.B.; Fryer, C.J.; Jackson, E.C.; Welch, T.R.; McEnery, P.T.; West, C.D. Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics 1986, 78, 861–865. [Google Scholar]
- Pennisi, A.J.; Takahashi, M.; Bernstein, B.H.; Singsen, B.H.; Uittenbogaart, C.; Ettenger, R.B.; Malekzadeh, M.H.; Hanson, V.; Fine, R.N. Minoxidil therapy in children with severe hypertension. J. Pediatr. 1977, 90, 813–819. [Google Scholar] [PubMed]
- Puri, H.C.; Maltz, H.E.; Kaiser, B.A.; Potter, D.E. Severe hypertension in children with renal disease: Treatment with minoxidil. Am. J. Kidney Dis. 1983, 3, 71–75. [Google Scholar] [CrossRef]
- Jerjen, R.; Koh, W.-L.; Sinclair, R.; Bhoyrul, B. Low-dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome. Br. J. Dermatol. 2021, 184, 977–978. [Google Scholar] [CrossRef]
- Meyers, R.S.; Siu, A. Pharmacotherapy review of chronic pediatric hypertension. Clin. Ther. 2011, 33, 1331–1356. [Google Scholar] [CrossRef] [PubMed]
- Jimenez-Cauhe, J.; Saceda-Corralo, D.; Rodrigues-Barata, R.; Hermosa-Gelbard, A.; Moreno-Arrones, O.M.; Gil-Redondo, R.; Ortega-Quijano, D.; Fernandez-Nieto, D.; Jaen-Olasolo, P.; Vaño-Galvan, S. Characterization and management of hypertrichosis induced by low-dose oral minoxidil in the treatment of hair loss. J. Am. Acad. Dermatol. 2021, 84, 222–223. [Google Scholar] [CrossRef] [PubMed]
Variable | Mean (SD)/% (n/N) |
---|---|
N = 20 patients | |
Sex | Male: 60% (12/20) |
Female: 40% (8/20) | |
Age (years) | 3.89 (SD 3.82) |
Weight (kg) | 16.29 (SD9.71) |
Duration of treatment (days) | 38.3 (SD 38.68) |
Daily dose (mg/24 h) | 13.22 (SD 8.23) |
Adjusted dose (mg/kg/day) | 0.90 (SD 0.43) |
Accumulated dose (mg) | 453.75 (SD 513.36) |
Appearance of hypertrichosis | Yes: 65% (13/20) |
No: 35% (7/20) | |
Onset latency time for hypertrichosis (days) | 24.31 (SD 19.77) |
Resolution of hypertrichosis | Yes: 61.5% (8/13) |
No: 38.5% (5/13) | |
Onset latency time for resolution (days) | 76.25 (SD 29.25) |
Patient Group | Hypertrichosis | No Hypertrichosis | p Value |
---|---|---|---|
Median total daily dose (mg/day) | 10 | 10 | 0.497 |
Median adjusted daily dose (mg/kg/day) | 0.85 | 0.91 | 0.395 |
Median accumulated total dose (mg) | 300 | 240 | 0.13 |
Median treatment time (days) | 30 | 12 | 0.028 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sánchez-Díaz, M.; López-Delgado, D.; Montero-Vílchez, T.; Salvador-Rodríguez, L.; Molina-Leyva, A.; Tercedor-Sánchez, J.; Arias-Santiago, S. Systemic Minoxidil Accidental Exposure in a Paediatric Population: A Case Series Study of Cutaneous and Systemic Side Effects. J. Clin. Med. 2021, 10, 4257. https://doi.org/10.3390/jcm10184257
Sánchez-Díaz M, López-Delgado D, Montero-Vílchez T, Salvador-Rodríguez L, Molina-Leyva A, Tercedor-Sánchez J, Arias-Santiago S. Systemic Minoxidil Accidental Exposure in a Paediatric Population: A Case Series Study of Cutaneous and Systemic Side Effects. Journal of Clinical Medicine. 2021; 10(18):4257. https://doi.org/10.3390/jcm10184257
Chicago/Turabian StyleSánchez-Díaz, Manuel, David López-Delgado, Trinidad Montero-Vílchez, Luis Salvador-Rodríguez, Alejandro Molina-Leyva, Jesús Tercedor-Sánchez, and Salvador Arias-Santiago. 2021. "Systemic Minoxidil Accidental Exposure in a Paediatric Population: A Case Series Study of Cutaneous and Systemic Side Effects" Journal of Clinical Medicine 10, no. 18: 4257. https://doi.org/10.3390/jcm10184257